ATTD: Advanced Technologies and Treatments for Diabetes

In this episode, host Bob Gabbay and his guest, Dr George Grunberger, Chairman of the Grunberger Diabetes Institute, discuss best practice and guidance around basal insulin and GLP-1 combinations.
They discuss:
What exactly fixed-ratio combinations are and the problems they tackle

Identifying patient candidates and timelines for starting FRCs

Meaningful benefits of FRCs compared with basal insulin alone

Concerns and limitations of FRCs

How guideline recommendations currently position FRCs in diabetes management

Dr George Grunberger, Chairman of the Grunberger Diabetes Institute in Michigan. George is also Clinical Professor of Internal Medicine at Wayne State University School of Medicine, and Professor of Internal Medicine at Oakland University William Beaumont School of Medicine.
Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!
Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In this episode, host Bob Gabbay and his guest, Dr William Polonsky discuss safe and effective titration strategies, and the importance of collaborating with your patient.
They discuss:
The importance of titration in successful insulin therapy

Barriers to titration, including patient self-management

How clinicians can collaborate with patients in their titration journey

The importance of language used by clinicians

Practical tips for simplifying titration in busy clinical settings

Dr. Polonsky is President and Founder of the Behavioral Diabetes Institute, and Associate Clinical Professor in Psychiatry at the University of California.
Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!
Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In this episode, host Bob Gabbay and his guest, Dr Osama Hamdy, discuss how clinicians can identify patients for insulin initiation in Type 2 diabetes.
They discuss:
When clinicians should consider insulin for patients with T2D

Addressing concerns of weight gain with insulin

ADA/EASD recommendations

Barriers to insulin therapy and Type 2 diabetes

Advice on communication with patients

Dr Osama Hamdy is Associate Professor of Medicine at Harvard Medical School, and Director of the Obesity Clinical Program at the Joslin Diabetes Center.
Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!
Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In our new series, Insulin in Practice, host Dr Bob Gabbay looks at the principles of Basal Insulin Therapy in Type 2 Diabetes; its physiological role, pharmacodynamics, and current guideline-based use.
He is joined by Dr Giulio Romeo.
They discuss:
The role of basal insulin in normal physiology and why it matters in Type 2 diabetes

Goals of basal insulin therapy

What makes new basal insulins different

Current guidelines and recommendations for basal insulin therapy

Alternatives to basal insulin therapy

Tips for safe and effective initiation and titration

Dr Giulio Romeo is Associate Medical Director of the Adult Diabetes Section at Joslin Diabetes Center, and Assistant Professor of Medicine, Harvard Medical School.
Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!
Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In this episode of ATTD 2026 Conference Catch-Up, we dive into Advancements in Type 1 Diabetes: From Pathogenesis to Therapy, featuring the latest breakthroughs in understanding and treating Type 1 diabetes, from viral triggers to novel treatment strategies. 
Join us as we summarize key takeaways from these thought-provoking presentations: 
Role of Viruses in Pathogenesis of Type 1 Diabetes – Dr. Teresa Rodriguez-Calvo 

Dendritic Cells for Treatment of Type 1 Diabetes – Dr. Jason Gaglia 

C-Peptide: A Marker for Functional Beta Cell Mass? – Prof. Chantal Mathieu 

This episode is an essential listen for endocrinologists, researchers, and healthcare professionals specializing in diabetes care, providing insights into the evolving landscape of Type 1 diabetes pathogenesis and the potential of dendritic cell therapies. 
Enjoy the listen! 
This podcast was created using AI to provide a quick and insightful summary of an ATTD 2026 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information. 
ATTD 2026, the 19th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on 11-14 March, 2026, in Barcelona. https://attd.kenes.com